DGIdb - ENASIDENIB Drug Record

ENASIDENIB chembl:CHEMBL3989908 ApprovedAntineoplastic

Alternate Names:

AG 221
CC-90007 FREE BASE
ENASIDENIB
AG-221

Drug Info:

(3 More Sources)

Publications:

Stein et al., 2017, Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia., Blood
Yen et al., 2017, AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations., Cancer Discov
Medeiros BC et al., 2017, Isocitrate dehydrogenase mutations in myeloid malignancies., Leukemia

ENASIDENIB IDH2

Interaction Score: 41.22

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

Approval Status FDA approved

PMIDs:
28588020 28193778 27721426

Sources:
JAX-CKB CIViC PharmGKB FDA OncoKB
ENASIDENIB FLT3

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Enasidenib + Quizartinib

Indication/Tumor Type acute myeloid leukemia

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB

TTD: AG-221
- Version: 2020.06.01
Alternate Names:

D0K7FT TTD Drug ID

Drug Info:

Publications:

Dimitrov L et al., 2015, New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma., Int J Med Sci

JAX-CKB: Enasidenib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Stein et al., 2017, Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia., Blood

Yen et al., 2017, AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations., Cancer Discov

CIViC: ENASIDENIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Stein et al., 2017, Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia., Blood

Yen et al., 2017, AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations., Cancer Discov

OncoKB: Enasidenib
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL3989908
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
PharmGKB: enasidenib
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:
FDA: Enasidenib
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	acute myeloid leukemia
Response Type	sensitive
Approval Status	FDA approved

combination therapy	Enasidenib + Quizartinib
Indication/Tumor Type	acute myeloid leukemia
Response Type	predicted – sensitive

ENASIDENIB Drug Record

ENASIDENIB chembl:CHEMBL3989908 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

ENASIDENIB IDH2

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type acute myeloid leukemia Response Type sensitive Approval Status FDA approved

PMIDs: 28588020 28193778 27721426

Sources: JAX-CKB CIViC PharmGKB FDA OncoKB

ENASIDENIB FLT3

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Enasidenib + Quizartinib Indication/Tumor Type acute myeloid leukemia Response Type predicted – sensitive

PMIDs: None found

Sources: JAX-CKB

TTD: AG-221

Alternate Names: D0K7FT TTD Drug ID

Drug Info:

Publications: Dimitrov L et al., 2015, New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma., Int J Med Sci

JAX-CKB: Enasidenib

Alternate Names:

Drug Info:

Publications: Stein et al., 2017, Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia., Blood Yen et al., 2017, AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations., Cancer Discov

CIViC: ENASIDENIB

Alternate Names:

Drug Info:

Publications: Stein et al., 2017, Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia., Blood Yen et al., 2017, AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations., Cancer Discov

OncoKB: Enasidenib

Alternate Names:

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL3989908

Alternate Names:

Drug Info:

Publications:

PharmGKB: enasidenib

Alternate Names:

Drug Info:

Publications:

FDA: Enasidenib

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

Approval Status FDA approved

PMIDs:
28588020 28193778 27721426

Sources:
JAX-CKB CIViC PharmGKB FDA OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Enasidenib + Quizartinib

Indication/Tumor Type acute myeloid leukemia

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB

Alternate Names:

D0K7FT TTD Drug ID

Publications:

Dimitrov L et al., 2015, New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma., Int J Med Sci

Publications:

Stein et al., 2017, Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia., Blood

Yen et al., 2017, AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations., Cancer Discov

Publications:

Stein et al., 2017, Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia., Blood

Yen et al., 2017, AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations., Cancer Discov